Quality standard
Update information
Update information
Minor changes since publication
January 2022: The rationale, definition and audience descriptors for statement 2 were amended to align with recommendation 1.1.11 in the updated NICE guideline on anaphylaxis and to reflect the advice on information people should be given about using their adrenaline auto-injector in the Medicines and Healthcare products Regulatory Agency (MHRA) Public Assessment Report of the Commission on Human Medicines' Adrenaline Auto-injector Expert Working Group. A link was added to statement 4 to highlight guidance on ongoing training for people with adrenaline auto-injectors that will be considered when this quality standard is next reviewed.